EcoDrugPlus

Solute Carrier Family 29 Member 1a

Ensembl ID : ENSTNIG00000017001
Gene Symbol: SLC29A1A
2 Cross references
209 Possible Orthologues:

Solute Carrier Family 5 Member 1

Ensembl ID : ENSTNIG00000009127
Gene Symbol: SLC5A1
2 Cross references
250 Possible Orthologues:

Solute Carrier Family 6 Member 1a

Ensembl ID : ENSTNIG00000012619
Gene Symbol: SLC6A1A
2 Cross references
205 Possible Orthologues:

Solute Carrier Family 6 Member 3

Ensembl ID : ENSTNIG00000007218
Gene Symbol: SLC6A3
2 Cross references
166 Possible Orthologues:

Solute Carrier Family 6 Member 4a

Ensembl ID : ENSTNIG00000004783
Gene Symbol: SLC6A4A
2 Cross references
201 Possible Orthologues:

Solute Carrier Family 6 Member 9

Ensembl ID : ENSTNIG00000007959
Gene Symbol: SLC6A9
2 Cross references
208 Possible Orthologues:

Solute Carrier Family 9 Member A3, Tandem Duplicate 2

Ensembl ID : ENSTNIG00000002637
Gene Symbol: SLC9A3.2
2 Cross references
234 Possible Orthologues:

Somatostatin Receptor 2

Ensembl ID : ENSTNIG00000000288
Gene Symbol: SSTR2
2 Cross references
192 Possible Orthologues:

Somatostatin Receptor 2

Ensembl ID : ENSTNIG00000007401
Gene Symbol: SSTR2
2 Cross references
192 Possible Orthologues:

Sphingosine Kinase 2

Ensembl ID : ENSTNIG00000008077
Gene Symbol: SPHK2
2 Cross references
200 Possible Orthologues:

Spleen Tyrosine Kinase

Ensembl ID : ENSTNIG00000007102
Gene Symbol: SYK
2 Cross references
200 Possible Orthologues:

Steroid-5-Alpha-Reductase, Alpha Polypeptide 2a

Ensembl ID : ENSTNIG00000000347
Gene Symbol: SRD5A2A
2 Cross references
207 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).